A diabetes medication lawsuit today most likely refers to one of several active product liability cases against the makers of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound, though separate lawsuits also target insulin pricing and contaminated metformin. As of mid-2026, thousands of cases are pending in federal multidistrict litigation, no global settlements have been reached in the GLP-1 cases, and the first bellwether trials are expected in late 2026 or early 2027.
GLP-1 Gastrointestinal Injury Lawsuits
The largest active diabetes drug litigation involves GLP-1 receptor agonists prescribed for type 2 diabetes and weight loss. The drugs at issue include Ozempic, Wegovy, and Rybelsus, made by Novo Nordisk, and Mounjaro, Zepbound, and Trulicity, made by Eli Lilly. Plaintiffs allege the manufacturers knew or should have known about serious side effects and failed to warn patients and doctors.
In February 2024, the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into MDL 3094, In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, in the U.S. District Court for the Eastern District of Pennsylvania. Judge Karen S. Marston oversees the proceeding. By June 2026, roughly 3,763 personal injury lawsuits were pending, with about 486 new cases added between August and September 2025 alone.
The injuries alleged include gastroparesis (stomach paralysis), ileus and intestinal obstruction, pancreatitis, gallbladder disease, acute kidney injury, and complications requiring surgery.
In August 2025, Judge Marston allowed the core failure-to-warn and breach-of-warranty claims to move forward while dismissing design defect claims and requests for medical monitoring. She also set a strict evidentiary standard for gastroparesis: plaintiffs must produce objective proof from a gastric emptying study. CT scans, MRIs, endoscopy, and other imaging methods were found insufficient on their own.
Both manufacturers have pushed to narrow the case. Eli Lilly and Novo Nordisk filed motions in January 2025 to dismiss multiple counts of the master complaint, arguing the FDA-approved labels are legally sufficient and that federal law preempts many claims. In June 2026, Eli Lilly filed additional motions to dismiss and to exclude plaintiffs’ expert witnesses. A May 2026 letter brief from Eli Lilly sought to expand preemption arguments to cover pancreatitis, malnutrition, and acute kidney injury claims.
GLP-1 Vision Loss Lawsuits
A separate wave of GLP-1 lawsuits alleges the drugs cause non-arteritic anterior ischemic optic neuropathy, or NAION, a condition that can produce sudden, permanent vision loss. In December 2025, the Judicial Panel consolidated these claims into MDL 3163, also before Judge Marston in the Eastern District of Pennsylvania.
By early 2026, more than 100 federal NAION claims had been filed, with over 600 additional cases pending in New Jersey state court. Plaintiffs frequently cite a 2024 study in JAMA Ophthalmology that found semaglutide users faced roughly seven times the risk of NAION compared to patients on other weight-loss treatments. The manufacturers have challenged the study’s methodology and disputed causation. In June 2025, the World Health Organization warned that semaglutide drugs may rarely cause NAION.
Judge Marston scheduled a “Science Day” for June 2, 2026, at which experts presented non-adversarial educational lectures on the biological relationship between GLP-1 drugs and ocular blood flow.
Settlement Outlook and Trial Schedule
No global settlements have been reached in either the gastrointestinal or vision loss litigation. Bellwether trials, in which representative cases go to juries to test the strength of the evidence on both sides, are expected to begin in late 2026 or early 2027.
Legal analysts have estimated potential total industry-wide liability at $2 billion or more across all claims, though the actual outcome depends heavily on how the bellwethers land. Projected settlement ranges for individual cases vary widely: $400,000 to $700,000 for severe gastroparesis cases, and potentially over $1 million for permanent vision loss.
FDA Warnings and the Novo Nordisk Enforcement Letters
The litigation has unfolded alongside a series of FDA label changes and enforcement actions that plaintiffs point to as evidence of undisclosed risks.
In September 2023, the FDA added warnings for ileus to the Ozempic label. In January 2025, the label was updated to state the drug is “not recommended in patients with severe gastroparesis” and to warn of “severe gastrointestinal adverse reactions.” In February 2026, the FDA updated the Zepbound label to include warnings for intestinal obstruction and severe constipation including fecal impaction.
The FDA has also acted directly against Novo Nordisk. In September 2025, the agency issued a warning letter finding that promotional materials for Wegovy, Ozempic, and Victoza misbranded the drugs by minimizing risks. The FDA flagged materials that characterized pancreatitis, gallbladder complications, and thyroid cancer risks as “overhyped” or “mild to moderate,” while failing to disclose risks related to suicidal behavior, heart rate increases, and contraindications for patients with certain thyroid conditions. The letter noted a pattern of misleading promotional communications dating back to 2010.
In March 2026, the FDA issued a second, more pointed warning letter after inspectors found that Novo Nordisk had systematically failed to report serious adverse events as required by law. The letter cited specific cases in which the company or its contractors improperly rejected or invalidated safety reports. One involved a patient death whose report was erroneously closed because the reporter was not a health care professional. Another involved a physician’s report that a semaglutide patient had committed suicide, which Novo Nordisk failed to pass along to the FDA. The company acknowledged the findings and said it would address the violations.
Insulin Pricing Litigation
A separate case, In re: Insulin Pricing Litigation (MDL 3080), is pending in the U.S. District Court for the District of New Jersey before Judge Brian R. Martinotti. As of late 2025, 516 cases were pending, up from 85 in December 2024.
The plaintiffs, including self-funded health plans, state attorneys general, counties, and major health systems, allege that insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi worked with pharmacy benefit managers CVS Caremark, Express Scripts, and OptumRx to artificially inflate insulin list prices through a cycle of escalating rebates and unfavorable formulary placement. The case expanded in early 2026 with new plaintiffs including several state attorneys general, health systems in multiple states, Hamilton County in Ohio, and The Toro Company.
No settlement has been reached in the MDL. Separately, in March 2023, Eli Lilly, Novo Nordisk, and Sanofi announced 70% price cuts, though those were corporate decisions rather than legal settlements.
Metformin NDMA Contamination Settlements
Metformin, one of the most commonly prescribed diabetes drugs, drew lawsuits after the FDA found that certain extended-release formulations were contaminated with NDMA, a probable human carcinogen. Beginning in May 2020, Amneal Pharmaceuticals and other generic manufacturers issued voluntary recalls. Lawsuits followed and were consolidated as In re Metformin Marketing and Sales Practices Litigation in the District of New Jersey.
In May 2026, the court granted preliminary approval for two settlements totaling $5.55 million: $3 million with Teva Pharmaceuticals and related entities, and $2.55 million with Granules USA and Heritage Pharmaceuticals. The settlements cover people who purchased metformin from those defendants between July 2015 and June 2020. A final approval hearing was scheduled for August 12, 2026. Litigation continues against other defendants.
Earlier Diabetes Drug Cases That Have Resolved
Older diabetes medications produced some of the largest pharmaceutical settlements in U.S. history and give a sense of how these cases can end.
More than 10,000 lawsuits alleged that Actos (pioglitazone), made by Takeda Pharmaceuticals, caused bladder cancer. In April 2014, a Louisiana jury in a bellwether case awarded $9 billion in punitive damages against Takeda and co-marketer Eli Lilly, though a judge later reduced the total to $36.8 million. In 2015, Takeda agreed to pay up to $2.4 billion to settle roughly 9,000 cases. More than 97% of plaintiffs accepted, with individual claims averaging about $296,000 to $300,000. Takeda did not admit guilt, and the MDL was formally closed in April 2018.
GlaxoSmithKline faced thousands of lawsuits over Avandia (rosiglitazone) after a 2007 analysis linked its use to a 43% increase in heart attack risk. In November 2011, GlaxoSmithKline reached a $3 billion settlement with the U.S. government resolving civil and criminal investigations into illegal marketing of multiple drugs, including Avandia. The company also set aside $3.4 billion for additional Avandia product liability claims after previously spending $2.36 billion to settle roughly 10,000 of 13,000 individual lawsuits and investigations.
The SGLT2 inhibitor Invokana (canagliflozin), made by Johnson & Johnson subsidiary Janssen Pharmaceuticals, drew roughly 1,100 liability lawsuits consolidated in 2017 in the District of New Jersey. Johnson & Johnson reached agreements to settle many of the cases in 2018, with settlement amounts kept confidential. The FDA has warned that the entire SGLT2 class is associated with Fournier’s gangrene, a rare and often fatal genital infection, and a study of FDA adverse event data identified 491 cases linked to SGLT2 inhibitors between 2013 and 2020.
How These Lawsuits Work and What You Need to File
Most diabetes medication lawsuits are not class actions. They are individual lawsuits consolidated into multidistrict litigation for pretrial efficiency. Each plaintiff keeps their own claim and must prove their own injuries. MDL consolidation lets a single judge handle discovery, motions, and procedural issues across thousands of cases, and bellwether trials test representative cases before juries so both sides can gauge the evidence.
To pursue a claim in the GLP-1 litigation, you generally need documented proof of drug use through prescriptions or insurance records, a diagnosis of a qualifying condition such as gastroparesis or NAION, and medical evidence connecting the injury to the medication. Courts have set high bars for certain injuries: Judge Marston’s August 2025 ruling requires gastroparesis plaintiffs to produce objective gastric emptying study results, not just a symptom-based diagnosis.
Filing deadlines vary by state. Statutes of limitations typically run two to three years from the date you discovered the injury and its potential link to the medication. Some states impose deadlines as short as one year. Missing the window generally results in permanent dismissal regardless of the merits of the claim.